In a significant legal win for GSK plc (NYSE:GSK), on Friday, a Florida State Court ruled in favor of the pharmaceutical giant, excluding the plaintiff’s expert testimonies that claimed ranitidine, a drug once sold under the Zantac brand, was a significant risk factor for prostate cancer. The court deemed the expert testimony unreliable, reinforcing the broader scientific consensus that ranitidine does not pose a consistent or reliable cancer risk. This decision aligns with a December 2022 ruling by Judge Rosenberg in the federal multidistrict litigation (MDL), which also dismissed expert evid…
